Prescription charges backfire on UK health and wealth Rather than generating revenue, it appears that charging people with long-term conditions for their medicines results in patients not filling their prescriptions with hidden costs for their health, for the NHS and for the UK economy as a whole.…
Prescription charges backfire on UK health and wealth Rather than generating revenue, it appears that charging people with long-term conditions for their medicines results in patients not filling their prescriptions with hidden costs for their health, for the NHS and for the UK economy as a whole.…
Scrap prescription charges for all long-term conditions, charities urge The cost of prescriptions is putting many patients off collecting the medicines they need, a new report has found.…
Informative video about biosimilar medicines for patientsThe National Rheumatoid Arthritis Society (NRAS) has put together a video about biosimilar medicines which are entering the UK market as originator biologic medicines come off-patent. We want to encourage pharmacists and their staff to signpost suitable patients who are currently being prescribed bi…
Anti-rheumatic works with anti-cancer drug to boost tumour cell death Researchers find that auranofin and RAPTA-T can work together to kill tumour cells.…
Osteoporosis drugs may cause microcracks in bone Bisphosphonates are prescribed to prevent fractures in osteoporosis, but new research suggests that, paradoxically, they can also cause tiny cracks in bone…
Why some patients are reluctant to take osteoporosis drugs There are a number of factors that contribute to patients’ fear and reluctance to take osteoporosis drugs, leaving them at increased risk of fractures.…
EMA recommends approval of tofacitinib for rheumatoid arthritis A drug to treat people with rheumatoid arthritis is now being recommended for use across the EU – four years after the same product was refused a licence because of safety concerns.…
EMA recommends approval for oral rheumatoid arthritis drug The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended that baricitinib (Olumiant; Eli Lilly), an oral therapy for rheumatoid arthritis (RA), is granted a marketing authorisation in the EU.…
DMARDs do not increase post-surgical infection risk Rates of post-surgical infections did not increase for patients taking disease-modifying anti-rheumatic drugs and biologics, researchers discover.…
